Company intelligence / Profile preview
Daré Bioscience, Inc.
San Diego, California, United Statesdarebioscience.com ↗
- Ownership
- Public · DARE
- Development stage
- Other
01
Overview
Daré has one FDA-approved product (XACIATO) for bacterial vaginosis. Other products are in various stages of development, with Sildenafil Cream 3.6% facing FDA delays for Phase 3 trials, leading the company to pursue a compounded version for market in Q4 2025.
- Therapeutic areas
- Women's HealthInfectious Diseases
- Modalities
- Topical creamsvaginal gelsintravaginal ringsimplants
- Industry
- Biotech
02
Drug pipeline
23 assets22 more assets in the full pipeline.
03
Partnerships
Organon (global license agreement for XACIATO)Bayer (licensed Ovaprene)Theramex (co-development and licensing agreement for Casea S)
04
Financials
- Market cap
- $9.3M
- Total revenue
- $1M
- Enterprise value
- $3.5M
Beyond the preview
Go deeper on Daré Bioscience, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Daré Bioscience, Inc..